Share on StockTwits

Investment analysts at Janney Montgomery Scott began coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a note issued to investors on Monday. The firm set a “buy” rating on the stock.

Shares of Marinus Pharmaceuticals (NASDAQ:MRNS) opened at 8.04 on Monday. Marinus Pharmaceuticals has a 52-week low of $8.00 and a 52-week high of $8.16. The stock’s 50-day moving average is $8.02 and its 200-day moving average is $8.02. The company’s market cap is $4.0 million.

Marinus Pharmaceuticals, Inc is a clinical stage biopharmaceutical company. The Company is focused on developing and commercializing neuropsychiatric therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.